H.C. Wainwright raised the firm’s price target on Larimar Therapeutics (LRMR) to $16 from $15 and keeps a Buy rating on the shares following the Q4 report. The firm says a submission for Nomlabofusp for accelerated approval is expected by the end of 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.